Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2024Influenza and Other Respiratory VirusesOpen Access

Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination

View Full Paper
Ask AI
Bookmark
Share

Authors

SYSalma YounesQatar UniversityENEleonora NicolaiSaint Camillus International University of Health and Medical SciencesMPMassimo PieriUniversity of Rome Tor Vergata

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Younes et al. (2024) studied this question.

synapsesocial.com/papers/68e6c5d3b6db6435876444f4https://doi.org/10.1111/irv.13290
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)2021 · 256 citations
  2. 2Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination2021 · 2,300 citations
  3. 3Waning Immunity after the BNT162b2 Vaccine in Israel2021 · 1,055 citations
  4. 4Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar2022 · 410 citations
  5. 5Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial2021 · 699 citations